Selective Laser Trabeculoplasty

Overview

Theprospective clinical studyof the selective laser trabeculoplasty(SLT)bymeansthe Coherent Selecta 7000 laser (wave length 532 nm) was conducted. Totally 108.7± 18.3 laser non-overlapping spots (mean energy level 1.04 ± 0.22 mJ) along thewhole circle of the trabecular meshwork in the anterior chamber angle wereapplied. The study included 258 eyes of 146 patients (50 of them were men) withglaucoma. The mean age of the whole group was 55.9 ± 13.7 years. The group ofunsuccessfully treated patients (30 patients, 41 eyes) in whom the intraocularpressure (IOP) elevated from 23.2 ± 3.7 mm Hg in 4.7 % (measured 493 ± 474 daysafter the treatment) during the followup,wasremoved fromthe study. In the groupwith good response to the SLT, 116 patients (217 eyes) were evaluated 650 ± 405days after treatment. Before treatment, in this group the IOP was 23.9 ± 3.0 mmHg, at the end of the study the IOP was lowered by 4.5 ± 2.9 mm Hg, in total by18.6 %. IOP decrease was more pronounced in patients with higher level of IOP atthe beginning. Immediately after SLT, no significant rising of the IOP level wasrecorded. Selective laser trabeculoplasty preserves the integrity of the trabecularmeshwork of the anterior chamber angle, and is a safe and clinically effectivemethod of treatment of different forms of glaucoma and ocular hypertension.

Key words:
glaucoma, laser trabeculoplasty, SELECTA laser